top of page

Poster Listing



AAV next generation vectors

Mathieu Mevel

Nantes Université, CHU de Nantes, TaRGeT - Translational Research in Gene Therapy, INSERM UMR 1089, F-44200 Nantes, France

Chemically-engineered recombinant Adeno-Associated Virus: how chemistry improve rAAV liver gene delivery


AAV next generation vectors

Kathleen Börner

Asklepios BioPharmaceutical (AskBio), Heidelberg, Germany

Characterisation of AAVs in NHPs and rodents using the AskBio Capsid screening (ABCs) platform


AAV next generation vectors

John Mitchell

Montreal Children’s Hospital, Montreal, Quebec

Sustained efficacy and safety up to 3.5 years in adults with glycogen storage disease type Ia (GSDIa): longer-term results from a phase 1/2 clinical trial of DTX401, an AAV8-mediated, liver-directed gene therapy


AAV next generation vectors

Verena Mehlfeld

ViGeneron GmbH

A novel dual AAV approach for intravitreal gene therapy of Stargardt disease


AAV next generation vectors

David Anderson

SwanBio Therapeutics, Inc., PA 19004, USA

Selection of clinical doses for SBT101, an AAV9-hABCD1 vector for the treatment of adrenomyeloneuropathy


AAV next generation vectors

Jessica Wiseman

University of Sheffield

Gene Replacement Therapy for Spastic Paraplegia 47


AAV next generation vectors

David Anderson

SwanBio Therapeutics, Inc., PA 19004, USA

Optimization of intrathecal delivery of an infused AAV9 vector for delivery of a gene therapy candidate for adrenomyeloneuropathy in non-human primates


AAV next generation vectors

James Zengel

Department of Microbiology and Immunology, Stanford University School of Medicine

Hardwiring tissue-specific AAV transduction in mice through engineered receptor expression


AAV next generation vectors

Christian Schön

Boehringer-Ingelheim Pharma GmbH & Co. KG

Characterization of engineered AAV capsids in the retina of mice and in two novel human retina ex vivo models


AAV next generation vectors

Hiroyuki Nakai

Oregon Health & Science University

Barcode screening identifies AAV-KP1 as an AAV capsid that efficiently transduces pancreatic islets with minimal off-target consequences following retrograde pancreatic duct injection in non-human primates


AAV next generation vectors

Jennifer Green

Solid Biosciences

Further characterization of a novel AAV vector and expanded selection criteria platform for muscle gene delivery


AAV next generation vectors

Luned Badder

Division of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, Wales

Delivery of suicide therapies using a precision virotherapy; novel approaches for pancreatic cancer

bottom of page